期刊文献+

PGC-1α与肿瘤代谢关系的研究进展 被引量:4

Advances in relationship between PGC-1α and tumor metabolism
原文传递
导出
摘要 近年来,针对肿瘤代谢的研究已经成为肿瘤研究的新热点,而对代谢过程中关键调控因子的研究更是肿瘤代谢研究的重中之重,转录辅激活因子过氧化物酶体增殖物激活受体γ辅激活因子1α(peroxisome proliferators activated receptor gamma co-activator 1 alpha,PGC-1α)便是其中之一。PGC-1α是线粒体生物合成的关键调控因子,其在多种代谢性疾病中扮演着重要的角色,是氧化代谢和合成代谢的关键节点,参与了肿瘤代谢的调节,可以从氧化代谢和合成代谢两个方面调控肿瘤细胞的存活、增殖和迁移。本文对PGC-1α的结构及其相关转录因子进行了综述,探讨PGC-1α通过代谢调节肿瘤发生和发展的机制,并重点阐述了PGC-1α在肿瘤代谢研究中的进展,以期为后续以PGC-1α为靶标的抗肿瘤代谢的基础研究及药物研发提供新的理论参考。 The research on tumor metabolism has become a new hotspot in recent years, of which the key regulatory molecules that mediating tumor metabolism are a priority for all. The transcriptional co- activator peroxisome proliferator-activated receptor gamma co- activator 1alpha (PGC-1α) is one of these key regulatory molecules. PGC-1α has been demonstrated to be a crucial regulatory molecule involved in a variety of metabolic diseases. It is also a key molecule in regulation of tumor metabolism, mediating oxidative metabolism and anabolism to participate in regulation of survival, proliferation and migration of tumor cells. This paper reviews the advances in research on structure of PGC-la and its related transcription molecules, and explores the mechanism of PGC-1α in regulation of occurrence and development of tumors, especiallyfocuses on advances in the role of PGC-1α in tumor metabolism, which may provide theoretical references for fundamental studies on antitumor metabolism based on PGC-1α target as well as the related drug development.
出处 《肿瘤》 CAS CSCD 北大核心 2015年第10期1158-1162,共5页 Tumor
基金 国家自然科学基金资助项目(编号:81173174 81202655 81403260) 2013年江苏高校优秀科技创新团队计划[编号:苏教科(2013)10号] 江苏省中药学优势学科[编号:苏政办发(2014)37号] 中国博士后科学基金(编号:2014M551639) 江苏省博士后资助项目(编号:1401138C) 江苏省自然科学基金(编号:BK2012854) 江苏省2014年度普通高校研究生科研创新计划项目(编号:KYZZ_0270)~~
关键词 肿瘤 过氧化物酶体增殖物激活受体 代谢 转录激活因子类 Neoplasms Peroxisome proliferator-activatedreceptor Metabolism Activating transcription factors
  • 相关文献

参考文献40

  • 1Puigserver P, Wu Z, Park CW, et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis[J]. Cell, 1998, 92(6):829-839.
  • 2Sharma DR, Sunkaria A, Wani WY, et al. Aluminium induced oxidative stress results in decreased mitochondrial biogenesis via modulation of PGC- 1 alpha expression[Jl. Toxicol Appl Pharmacol, 2013,273(2):365-380.
  • 3Yuan C, Nguyen P, BaxterJD, et al. Distinct ligand-dependent and independent modes of thyroid hormone receptor (TR)/PGC-lalpha interactionU]. J Steroid Biochem Mol Biol. 2013. 133:58-65.
  • 4Arany Z, Foo SY, Ma Y, et al. HIF- independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-lalpha[J]. Nature, 2008, 451(7181):1008-1012.
  • 5Pooya S, Blaise S, Moreno GM, et al. Methyl donor deficiency impairs fatty acid oxidation through PGC-lalpha hypomethylation and decreased ER- alpha, ERR-alpha, and HNF-4alpha in the rat liver[J].J Hepatol, 2012, 57(2):344-351.
  • 6Valtat B, Riveline JP, Zhang P, et al. Fetal PGC-lalpha overexpression programs adult pancreatic beta- cell dysfunction[J]. Diabetes, 2013, 62(4): 1206-1216.
  • 7Roberts-Wilson TK, Reddy RN, Bailey JL, et al. Calcineurin signaling and PGC-lalpha expression are suppressed during muscle atrophy due to diabetes[J]. Biochim 8iophys Acta, 2010, 1803(8):960-967.
  • 8Hao Q, Hansen JB, Petersen RK, etal. ADD1 / SREBPlc activates the PGC-lalpha promoter in brown adipocytes[J]. Biochim Biophys Acta, 2010, 1801 (4):421-429.
  • 9Puigserver P. Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC-lalpha[J]. Int J Obes (Lond), 2005, 29 Suppl 1:$5-$9.
  • 10Rowe GC, Jiang A, Arany Z. PGC-1 coactivators in cardiac development and disease[J]. Circ Res, 2010, 107(7):825-838.

二级参考文献29

  • 1Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort[J]. Eur J Cancer, 2012,48(1):94-100.
  • 2SosmanJA. Kim KB,SchuchterL.,erai. Survival in BRAF V600-mutant advanced melanoma treated with vernurafentb[J]. N Engl Med, 2012, 366(8):707-714.
  • 3McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study[J]. Lancet Oncol, 2014, 15(3):323-332.
  • 4Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multi centre, open-label, phase 3 randomised controlled trtal[J]. Lancet, 2012, 380(9839):358-365.
  • 5Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/ mTOR inhibitors overcome acquired resistance to the BRAF Inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK rnutatlonslll. Mol Cancer Ther, 2012, 11 (4):909-920.
  • 6Das Thakur M, Salangsang F, Landman AS, et al. Modelling vemurafenlb resistance In melanoma reveals a strategy to forestall drug reslstance[J]. Nature, 2013, 494(7436):251-255.
  • 7Flaherty KT, Infante JR, Daud A, er at. Combined BRAF and MEK Inhibition In melanoma with BRAF V600 mutattons[J]. N Engl J Med, 2012, 367(18):1694-1703.
  • 8Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK Inhibition In BRAF-mutated melanoma[J]. N Engl J Med, 2012, 367(2):107-114.
  • 9Carvajal RD, Sosman JA, Quevedo JF, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trlal[J]. JAMA, 2014, 311 (23):2397-2405.
  • 10Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised studv[J]. Lancet Oncol, 2013, 14(8):733-740.

同被引文献35

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部